Showing 2691-2700 of 23150 results for "".
Advancing HER2-Targeted Therapy in GI Cancers
https://reachmd.com/programs/project-oncology/her2-targeted-therapy-gi-cancer/49170/The treatment landscape for HER2-positive gastroesophageal cancer is rapidly evolving, with zanidatamab emerging as a new option following years of limited progress beyond trastuzumab. Dr. John Strickler joins us to share insights on how recent FDA approvals and novel agents are transforming outcomeTailoring Pediatric Acne Care: A Look at Topical and Systemic Options
https://reachmd.com/programs/clinicians-roundtable/tailoring-pediatric-acne-care-a-look-at-topical-and-systemic-options/30055/Discover insights on how to effectively tailor pediatric acne management as improved treatment options become available.Public Health Disparities in Alzheimer's Disease and Brain Health
https://reachmd.com/programs/neurofrontiers/public-health-disparities-in-alzheimers-disease-and-brain-health/18072/Alzheimer's disease (AD) disproportionately impacts Black Americans.Anatomy Meets Function – Correlating Imaging with Symptoms
https://reachmd.com/programs/cme/Anatomy-Meets-Function-Correlating-Imaging-with-Symptoms/35966/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
https://reachmd.com/programs/project-oncology/supplements-and-cannabis-in-breast-cancer-care-an-integrative-medicine-approach/26409/Here’s how we can use an integrative medicine approach to balance evidence-based guidance on supplements and cannabis with patients’ goals.Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
https://reachmd.com/programs/project-oncology/axatilimab-for-cgvhd-assessing-organ-specific-responses-in-agave-201/36313/An analysis of the AGAVE-201 trial presented at the European Hematology Association 2025 Congress evaluated the organ-specific responses to axatilimab in patients with chronic graft-versus-host disease (cGVHD). Finding a range of effects, these results could offer new insights into dose optimizationExamining Psoriasis Prevalence: Diagnostic Differences Across Demographics
https://reachmd.com/programs/frontlines-psoriasis/examining-psoriasis-prevalence-diagnostic-differences-across-demographics/32432/Psoriasis affects nearly eight million adults in the US, but its impact isn’t felt equally; significant disparities in diagnosis exist across race, ethnicity, and socioeconomic status. Join Dr. Joe Tung as he discusses his recent analysis of data from the National Health Interview Survey, in which hAdjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
https://reachmd.com/programs/project-oncology/adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma/36306/Five years after treatment, the impact of adjuvant nivolumab still holds strong in high-risk muscle invasive urothelial carcinoma. Join Drs. Brian McDonough and Matthew Galsky as they review the CheckMate 274 trial’s long-term data, which show sustained disease-free survival and highlight ctDNA’s poADHD in Older Adults: Key Diagnostic and Treatment Strategies
https://reachmd.com/programs/neurofrontiers/adhd-in-older-adults-key-diagnostic-and-treatment-strategies/18152/Tune in to find out how you can diagnose and treat older adults with ADHD.The Future of Immunotherapy: Advancing Care in Endometrial Cancer
https://reachmd.com/programs/project-oncology/future-immunotherapy-endometrial-cancer/39932/Immunotherapy is a key treatment option for advanced and recurrent endometrial cancer, yet response rates remain variable—even in patients with mismatch repair-deficient tumors. Hear from Dr. Casey Cosgrove as he explores emerging strategies to enhance immune responsiveness, better predict tr